Beneficiaries in certain other arrangements, however, are not eligible to participate unless they are also enrolled in a standalone PDP, as applicable
The column was pre-equilibrated with 10 column volumes (CV) of 1 Dulbeccos Phosphate Buffered Saline (DPBS) (pH 7.4) (Sigma-Aldrich)/0.05% (v/v) sodium azide (Sigma-Aldrich), before the supernatant was loaded onto the column at a flow rate of (0.52) mL/min
Complementary care during medical treatments
Treatment options include dietary modifications, such as eliminating corn, wheat/gluten, soy, dairy, sugar, artificial sweeteners, yeast, and genetically modified foods
A Randomized Controlled Trial of the GLP-1 Receptor Agonist Dulaglutide in Primary Polydipsia. The Journal of Clinical Investigation